S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI" (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI" (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
1907, 1929, 1998, 2007--and now 2023? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI" (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI" (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
1907, 1929, 1998, 2007--and now 2023? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI" (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI" (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
1907, 1929, 1998, 2007--and now 2023? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI" (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI" (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
1907, 1929, 1998, 2007--and now 2023? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
NASDAQ:MTP

Biodexa Pharmaceuticals (MTP) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.29
▼
$3.22
52-Week Range
N/A
Volume
164,300 shs
Average Volume
57,354 shs
Market Capitalization
$6.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

MTP stock logo

About Biodexa Pharmaceuticals (NASDAQ:MTP) Stock

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.


MTP Stock News Headlines

July 8, 2023 | benzinga.com
Biodexa Pharmaceuticals PLC Announces Results Of Appeal Of Delisting Determination
April 25, 2023 | seekingalpha.com
BDRX Biodexa Pharmaceuticals Plc
October 3, 2023 | Legacy Research (Ad)
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)
“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”
April 4, 2023 | finance.yahoo.com
Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
March 28, 2023 | investorplace.com
Why Is Midatech Pharma (BDRX) Stock Up 64% Today?
February 9, 2023 | finance.yahoo.com
Midatech Pharma PLC Announces Private Placement Raising US $6.0 million
January 23, 2023 | financialpost.com
Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc
January 12, 2023 | finance.yahoo.com
Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study
October 3, 2023 | Legacy Research (Ad)
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)
“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”
January 3, 2023 | finance.yahoo.com
BIOAF: Merger with Midatech Pharma
December 13, 2022 | finance.yahoo.com
Midatech Pharma PLC Announces Proposed Acquisition of Bioasis Technologies Inc
December 13, 2022 | finance.yahoo.com
Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc
October 11, 2022 | seekingalpha.com
MTP Midatech Pharma plc
September 14, 2022 | marketwatch.com
Midatech Pharma Will Need Extra Financing in 1Q 2023; Mulling Options
September 14, 2022 | finance.yahoo.com
Midatech Pharma PLC Announces ADR Ratio Change
August 3, 2022 | thestreet.com
Midatech Pharma PLC News
June 21, 2022 | finance.yahoo.com
Midatech Pharma PLC Announces MTX110 Development for the Treatment of Glioma
June 10, 2022 | yahoo.com
Midatech Pharma PLC - MTX110 Study to be Presented at ISPNO 2022
June 7, 2022 | uk.investing.com
Midatech Pharma: MTX110’s Path To Market Fast-Tracked In RGBM
June 1, 2022 | seekingalpha.com
Midatech Pharma climbs on FDA’s Fast Track Designation for brain tumor candidate
June 1, 2022 | finance.yahoo.com
Midatech's investigational glioblastoma treatment gets Fast Track status
April 14, 2022 | seekingalpha.com
Midatech Pharma receives noncompliance notice from Nasdaq
March 8, 2022 | finance.yahoo.com
Midatech Pharma PLC Announces Appointment of Nominated and Financial Adviser
December 13, 2021 | finance.yahoo.com
Midatech Pharma PLC Announces IND Application for MTX110 Study in GBM Effective
November 27, 2021 | nasdaq.com
Midatech Pharma Plc - ADR Shares Approach 52-Week Low - Market Mover
September 17, 2021 | benzinga.com
Midatech Pharma Reported H1 Revenue +157% to 430K STG; H1 Operating Loss -3.15M vs -17.42M YoY
August 20, 2021 | nasdaq.com
Midatech Pharma PLC American Depositary Shs (MTP)
See More Headlines
Receive MTP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MTP Company Calendar

Today
10/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MTP
CUSIP
N/A
CIK
1643918
Web
www.midatechpharma.com
Phone
441235888300
Fax
N/A
Employees
18
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$800,000.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.67 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
21,670,000
Free Float
21,595,000
Market Cap
$6.18 million
Optionable
Not Optionable
Beta
2.29
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Stephen Anthony Stamp
    Chief Executive Officer, CFO, Secretary & Director
  • Dmitry Zamoryakhin
    Chief Scientific Officer
  • Dan Palmer
    Vice President-Technology
  • Steve Ellul
    Vice President-Business Development
  • Fiona Sharp
    Group Financial Controller

Key Competitors

View All Competitors













MTP Stock - Frequently Asked Questions

When did Biodexa Pharmaceuticals' stock split?

Biodexa Pharmaceuticals shares reverse split before market open on Monday, March 27th 2023. The 1-4 reverse split was announced on Monday, March 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Biodexa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biodexa Pharmaceuticals investors own include CRISPR Therapeutics (CRSP), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), Vaxart (VXRT), Nabriva Therapeutics (NBRV), Novavax (NVAX), Plug Power (PLUG), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

What is Biodexa Pharmaceuticals' stock symbol?

Biodexa Pharmaceuticals trades on the NASDAQ under the ticker symbol "MTP."

How much money does Biodexa Pharmaceuticals make?

Biodexa Pharmaceuticals (NASDAQ:MTP) has a market capitalization of $0.00 and generates $800,000.00 in revenue each year.

How can I contact Biodexa Pharmaceuticals?

Biodexa Pharmaceuticals' mailing address is ODDFELLOWS HOUSE 19 NEWPORT ROAD, CARDIFF X0, CF24 0AA. The official website for the company is www.midatechpharma.com. The company can be reached via phone at 441235888300 or via email at ir@midatechpharma.com.

This page (NASDAQ:MTP) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -